P53 in neurodegenerative diseases and brain cancers

Pharmacology and Therapeutics

Volumn 142, Issue 1, 2014, Pages 99-113

  Checler, Frédéric ^a   Alves Da Costa, Cristine ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Alzheimer's disease; Cerebral cancers; p53; Parkinson's disease; Signaling; Therapeutics

Indexed keywords

GELDANAMYCIN; PROTEIN P53; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; ARTICLE; BRAIN CANCER; DEGENERATIVE DISEASE; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; CEREBRAL CANCERS; P53; PARKINSON'S DISEASE; SIGNALING; THERAPEUTICS;

ANIMALS; BRAIN NEOPLASMS; GENETIC THERAPY; HUMANS; NEURODEGENERATIVE DISEASES; PRIONS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896740535     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.11.009     Document Type: Review

References (365)

1. A. Aguzzi, and M. Polymenidou Mammalian prion biology: one century of evolving concepts Cell 116 2004 1 20
2. D. Albani, E. Peverelli, R. Rametta, S. Batelli, L. Veschini, and A. Negro et al. Protective effect of TAT-delivered a-synuclein: relevance of the C-terminal domain and involvement of HSP70 FASEB J 18 2004 1713 1715
3. N. Allende-Vega, and M.K. Saville Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy Semin Cancer Biol 20 2010 29 39
4. H.C. Altmeppen, J. Prox, B. Puig, M.A. Kluth, C. Bernreuther, and D. Thurm et al. Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo Mol Neurodegener 6 2011 36
5. C. Alves da Costa Recent advances on a-synuclein cell biology: functions and dysfunctions Curr Mol Med 3 2003 17 24
6. C. Alves da Costa Recent insights on the pro-apoptotic phenotype elicited by presenilin 2 and its caspase and presenilinase-derived fragments Curr Alzheimer Res 2 2005 507 514
7. C. Alves da Costa, M.P. Mattson, K. Ancolio, and F. Checler The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis, a function independent of the presenilinase-derived N-terminal counterpart J Biol Chem 278 2003 12064 12069
8. C. Alves da Costa, E. Paitel, M.P. Mattson, R. Amson, A. Telerman, and K. Ancolio et al. Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons Proc Natl Acad Sci U S A 99 2002 4043 4048
9. C. Alves Da Costa, E. Paitel, B. Vincent, and F. Checler Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease J Biol Chem 277 2002 50980 50984
10. C. Alves da Costa, C. Sunyach, R. Pardossi-Piquard, J. Sevalle, B. Vincent, and N. Boyer et al. Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease J Neurosci 26 2006 6377 6385
11. M. Amici, V. Cecarini, M. Cuccioloni, M. Angeletti, S. Barocci, and G. Rossi et al. Interplay between 20S proteasomes and prion proteins in scrapie disease J Neurosci Res 88 2010 191 201
12. V. Anantharam, A. Kanthasamy, C.J. Choi, D.P. Martin, C. Latchoumycandane, and J.A. Richt et al. Opposing roles of prion protein in oxidative stress- and ER stress-induced apoptotic signaling Free Radic Biol Med 45 2008 1530 1541
13. A.J. Anderson, S. Stoltzner, F. Lai, J. Su, and R.A. Nixon Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL Neurobiol Aging 21 2000 511 524
14. A.J. Anderson, J.H. Su, and C.W. Cotman DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay J Neurosci 16 1996 1710 1719
15. M. Armogida, A. Petit, B. Vincent, S. Scarzello, C.A. da Costa, and F. Checler Endogenous beta-amyloid production in presenilin-deficient embryonic mouse fibroblasts Nat Cell Biol 3 2001 1030 1033
16. Y. Aylon, and M. Oren p53: guardian of ploidy Mol Oncol 5 2011 315 323
17. J.H. Bach, H.S. Chae, J.C. Rah, M.W. Lee, C.H. Park, and S.H. Choi et al. C-terminal fragment of amyloid precursor protein induces astrocytosis J Neurochem 78 2001 109 120
18. B.I. Bae, H. Xu, S. Igarashi, M. Fujimuro, N. Agrawal, and Y. Taya et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease Neuron 47 2005 29 41
19. A. Barzilai, and E. Melamed Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease Trends Mol Med 9 2003 126 132
20. C. Becker, G.P. Brobert, S. Johansson, S.S. Jick, and C.R. Meier Cancer risk in association with Parkinson disease: a population-based study Parkinsonism Relat Disord 16 2010 186 190
21. R. Beckerman, and C. Prives Transcriptional regulation by p53 Cold Spring Harb Perspect Biol 2 2010 a000935
22. A. Behin, K. Hoang-Xuan, A.F. Carpentier, and J.Y. Delattre Primary brain tumours in adults Lancet 361 2003 323 331
23. N.D. Belyaev, K.A. Kellett, C. Beckett, N.Z. Makova, T.J. Revett, and N.N. Nalivaeva et al. The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway J Biol Chem 285 2010 41443 41454
24. N.F. Bence, R.M. Sampat, and R.R. Kopito Impairment of the ubiquitin-proteasome system by protein aggregation Science 292 2001 1552 1555
25. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat Neurosci 3 2000 1301 1306
26. S.C. Biswas, E. Ryu, C. Park, C. Malagelada, and L.A. Greene Puma and p53 play required roles in death evoked in a cellular model of Parkinson disease Neurochem Res 30 2005 839 845
27. M.V. Blagosklonny, J. Toretsky, S. Bohen, and L. Neckers Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90 Proc Natl Acad Sci U S A 93 1996 8379 8383
28. F. Blandini, E. Sinforiani, C. Pacchetti, A. Samuele, E. Bazzini, and R. Zangaglia et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease Neurology 66 2006 529 534
29. F.E. Bleeker, R.J. Molenaar, and S. Leenstra Recent advances in the molecular understanding of glioblastoma J Neurooncol 108 2012 11 27
30. G.T. Bommer, I. Gerin, Y. Feng, A.J. Kaczorowski, R. Kuick, and R.E. Love et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes Curr Biol 17 2007 1298 1307
31. V. Bonifati, P. Rizzu, M.J. van Baren, O. Schaap, G.J. Breedveld, and E. Krieger et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism Science 299 2003 256 259
32. G. Bossi, G. Mazzaro, A. Porrello, M. Crescenzi, S. Soddu, and A. Sacchi Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy Oncogene 23 2004 418 425
33. G. Bossi, and A. Sacchi Restoration of wild-type p53 function in human cancer: relevance for tumor therapy Head Neck 29 2007 272 284
34. J.C. Bourdon, V. De Laurenzi, G. Melino, and D.P. Lane p53: 25 years of research and more questions to answer Cell Death Diff 10 2003 397 399
35. C. Braicu, V. Pileczki, A. Irimie, and I. Berindan-Neagoe p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells Mol Cell Biochem 381 2013 61 68
36. S. Brandner, S. Isenmann, A. Raeber, M. Fischer, A. Sailer, and Y. Kobayashi et al. Normal host prion protein necessary for scrapie-induced neurotoxicity Nature 379 1996 339 343
37. S. Bretaud, C. Allen, P.W. Ingham, and O. Bandmann p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease J Neurochem 100 2007 1626 1635
38. D.R. Brown PrPSc-like prion protein peptide inhibits the function of cellular prion protein Biochem J 352 Pt 2 2000 511 518
39. C.J. Brown, C.F. Cheok, C.S. Verma, and D.P. Lane Reactivation of p53: from peptides to small molecules Trends Pharmacol Sci 32 2011 53 62
40. C.J. Brown, S. Lain, C.S. Verma, A.R. Fersht, and D.P. Lane Awakening guardian angels: drugging the p53 pathway Nat Rev Cancer 9 2009 862 873
41. L. Buee, L. Troquier, S. Burnouf, K. Belarbi, A. Van der Jeugd, and T. Ahmed et al. From tau phosphorylation to tau aggregation: what about neuronal death? Biochem Soc Trans 38 2010 967 972
42. H. Büeler, A. Aguzzi, A. Sailer, R. Greiner, P. Autenried, and M. Aguet et al. Mice devoid of PrP are resistant to scrapie Cell 73 1993 1339 1347
43. L. Buizza, G. Cenini, C. Lanni, G. Ferrari-Toninelli, C. Prandelli, and S. Govoni et al. Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease PLoS One 7 2012 e29789
44. A.N. Bullock, and A.R. Fersht Rescuing the function of mutant p53 Nat Rev Cancer 1 2001 68 76
45. R.E. Burke alpha-Synuclein and Parkinson's disease Brain Res Bull 50 1999 465 466
46. A. Burton Possible role for p53 in Huntington's disease Lancet Neurol 4 2005 528 529
47. F.A. Caetano, M.H. Lopes, G.N. Hajj, C.F. Machado, C. Pinto Arantes, and A.C. Magalhaes et al. Endocytosis of prion protein is required for ERK1/2 signaling induced by stress-inducible protein 1 J Neurosci 28 2008 6691 6702
48. C. Caillava, S. Ranaldi, I. Lauritzen, C. Bauer, J. Fareh, and J.D. Abraham et al. Study on Ab34 Biology and Detection in Transgenic Mice Brain and Human CSF 2013 (Submitted for publication)
49. J.G. Cairncross, and D.R. Macdonald Successful chemotherapy for recurrent malignant oligodendroglioma Ann Neurol 23 1988 360 364
50. W.A. Campbell, H. Yang, H. Zetterberg, S. Baulac, J.A. Sears, and T. Liu et al. Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss J Neurochem 96 2006 1423 1440
51. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
52. V. Cecarini, L. Bonfili, M. Cuccioloni, M. Mozzicafreddo, M. Angeletti, and A.M. Eleuteri The relationship between the 20S proteasomes and prion-mediated neurodegenerations: potential therapeutic opportunities Apoptosis 15 2010 1322 1335
53. G. Cenini, R. Sultana, M. Memo, and D.A. Butterfield Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease J Cell Mol Med 12 2008 987 994
54. H. Chandler, and G. Peters Stressing the cell cycle in senescence and aging Curr Opin Cell Biol 25 2013 765 771
55. S. Chandra, G. Gallardo, R. Fernàndez-Chàcon, O.M. Schlüter, and T.C. Südhof a-synuclein cooperates with CSPa in preventing neurodegeneration Cell 123 2005 383 396
56. T.C. Chang, E.A. Wentzel, O.A. Kent, K. Ramachandran, M. Mullendore, and K. Lee et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis Mol Cell 26 2007 745 752
57. M. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, and S. Lincoln et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease Lancet 364 2004 1167 1169
58. F. Checler Processing of the b-amyloid precursor protein and its regulation in Alzheimer's disease J Neurochem 65 1995 1431 1444
59. F. Checler Alzheimer's and prion diseases: PDK1 at the crossroads Nat Med 19 2013 1088 1090
60. F. Checler, C. Alves da Costa, K. Ancolio, E. Lopez-Perez, and P. Marambaud Role of the proteasome in Alzheimer's disease Biochim Biophys Acta 1502 2000 133 138
61. F. Checler, J. Dunys, R. Pardossi-Piquard, and C. Alves da Costa p53 is regulated by and regulates members of the gamma-secretase complex Neurodegener Dis 7 2010 50 55
62. K. Chen, and N. Rajewsky The evolution of gene regulation by transcription factors and microRNAs Nat Rev Genet 8 2007 93 103
63. S.G. Chen, D.B. Teplow, P. Parchi, J.K. Teller, P. Gambetti, and L. Autilio-Gambetti Truncated forms of the human prion protein in normal brain and in prion disease J Biol Chem 270 1995 19173 19180
64. L.B. Chiarini, A.R. Freitas, S.M. Zanata, R.R. Brentani, V.R. Martins, and R. Linden Cellular prion protein transduces neuroprotective signals EMBO J 21 2002 3317 3326
65. H.S. Choi, S.H. Lee, S.Y. Kim, J.J. An, S.-I. Hwang, and D.W. Kim et al. Transduced Tat-a-synuclein protects against oxidative stress in vitro and in vivo Biochem Mol Biol 39 2006 253 262
66. J. Chou, N.H. Greig, D. Reiner, B.J. Hoffer, and Y. Wang Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian rats by the p53 inactivator PFT-alpha Cell Transplant 20 2011 1351 1359
67. D.H. Chui, E. Dobo, T. Makifuchi, H. Akiyama, S. Kawakatsu, and A. Petit et al. Apoptotic neurons in Alzheimer's disease frequently show intracellular Abeta42 labeling J Alzheimers Dis 3 2001 231 239
68. C. Colin, I. Virard, N. Baeza, A. Tchoghandjian, C. Fernandez, and C. Bouvier et al. Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis Neuropathol Appl Neurobiol 33 2007 431 439
69. J. Collinge Molecular neurology of prion disease J Neurol Neurosurg Psychiatry 76 2005 906 919
70. S.W. Coons, P.C. Johnson, B.W. Scheithauer, A.J. Yates, and D.K. Pearl Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas Cancer 79 1997 1381 1393
71. D.C. Corney, A. Flesken-Nikitin, A.K. Godwin, W. Wang, and A.Y. Nikitin MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth Cancer Res 67 2007 8433 8438
72. O. Corti, S. Lesage, and A. Brice What genetics tells us about the causes and mechanisms of Parkinson's disease Physiol Rev 91 2011 1161 1218
73. L.V. Crawford, D.C. Pim, E.G. Gurney, P. Goodfellow, and J. Taylor-Papadimitriou Detection of a common feature in several human tumor cell lines - a 53,000-dalton protein Proc Natl Acad Sci U S A 78 1981 41 45
74. C. Culmsee, and S. Landshamer Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders Curr Alzheimer Res 3 2006 269 283
75. C.A. da Costa DJ-1: a newcomer in Parkinson's disease pathology Curr Mol Med 7 2007 650 657
76. C.A. da Costa, K. Ancolio, and F. Checler Wild-type but not Parkinson's disease-related Ala53Thr-a-synuclein protect neuronal cells from apoptotic stimuli J Biol Chem 275 2000 24065 24069
77. C.A. da Costa, and F. Checler A novel parkin-mediated transcriptional function links p53 to familial Parkinson's disease Cell Cycle 9 2010 16 17
78. C.A. da Costa, and F. Checler Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism? Cell Signal 23 2011 963 968
79. C.A. da Costa, J. Dunys, F. Brau, S. Wilk, R. Cappai, and F. Checler 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation J Biol Chem 281 2006 9824 9831
80. C.A. da Costa, E. Masliah, and F. Checler β-Synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase-3 activation J Biol Chem 278 2003 37330 37335
81. C.A. da Costa, C. Sunyach, E. Giaime, A. West, O. Corti, and A. Brice et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease Nat Cell Biol 11 2009 1370 1375
82. G. Dasgupta, and J. Momand Geldanamycin prevents nuclear translocation of mutant p53 Exp Cell Res 237 1997 29 37
83. C.M. Davenport, I.G. Sevastou, C. Hooper, and J.M. Pocock Inhibiting p53 pathways in microglia attenuates microglial-evoked neurotoxicity following exposure to Alzheimer peptides J Neurochem 112 2010 552 563
84. S.M. de la Monte, Y.K. Sohn, and J.R. Wands Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease J Neurol Sci 152 1997 73 83
85. B. De Strooper, P. Saftig, K. Craessaerts, H. Vanderstichele, G. Guhde, and W. Annaert et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein Nature 391 1998 387 390
86. M. Demma, E. Maxwell, R. Ramos, L. Liang, C. Li, and D. Hesk et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53 J Biol Chem 285 2010 10198 10212
87. T. Devine, and M.S. Dai Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy Curr Pharm Des 19 2013 3248 3262
88. A. Diaz, L. De Jesus, L. Mendieta, M. Calvillo, B. Espinosa, and E. Zenteno et al. The amyloid-beta25-35 injection into the CA1 region of the neonatal rat hippocampus impairs the long-term memory because of an increase of nitric oxide Neurosci Lett 468 2010 151 155
89. T. Ding, X. Zhou, M. Kouadir, F. Shi, Y. Yang, and J. Liu et al. Cellular prion protein participates in the regulation of inflammatory response and apoptosis in BV2 microglia during infection with Mycobacterium bovis J Mol Neurosci 51 2013 118 126
90. L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr., and J.S. Butel et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 356 1992 215 221
91. S.C. Drew, C.L. Haigh, H.M. Klemm, C.L. Masters, S.J. Collins, and K.J. Barnham et al. Optical imaging detects apoptosis in the brain and peripheral organs of prion-infected mice J Neuropathol Exp Neurol 70 2011 143 150
92. W. Duan, X. Zhu, B. Ladenheim, Q.S. Yu, Z. Guo, and J. Oyler et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism Ann Neurol 52 2002 597 606
93. C. Dumanchin-Njock, C.A. Alves da Costa, L. Mercken, L. Pradier, and F. Checler The caspase-derived C-terminal fragment of betaAPP induces caspase-independent toxicity and triggers selective increase of Abeta42 in mammalian cells J Neurochem 78 2001 1153 1161
94. J. Dunys, T. Kawarai, J. Sevalle, V. Dolcini, P.S. George-Hyslop, and C.A. da Costa et al. p53-dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the {gamma}-secretase complex but is independent of its activity J Biol Chem 282 2007 10516 10525
95. J. Dunys, J. Sevalle, E. Giaime, R. Pardossi-Piquard, M.P. Vitek, and P. Renbaum et al. p53-dependent control of transactivation of the Pen2 promoter by presenilins J Cell Sci 122 2009 4003 4008
96. E. Duplan, E. Giaime, J. Viotti, J. Sevalle, O. Corti, and A. Brice et al. ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1 J Cell Sci 126 2013 2124 2133
97. E. Duplan, J. Sevalle, J. Viotti, T. Goiran, C. Druon, and P. Renbaum et al. Parkin differently regulates presenilin-1 and presenilin-2 function by direct control of their promoter transcription J Mol Cell Biol 5 2013 132 142
98. O. Eberhardt, and J.B. Schulz Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease Toxicol Lett 139 2003 135 151
99. D. Edbauer, C. Kaether, H. Steiner, and C. Haass Co-expression of nicastrin and presenilin rescues a loss of function mutant of APH-1 J Biol Chem 279 2004 37311 37315
100. W.S. el-Deiry, S.E. Kern, J.A. Pietenpol, K.W. Kinzler, and B. Vogelstein Definition of a consensus binding site for p53 Nat Genet 1 1992 45 49
101. D. Eliyahu, D. Michalovitz, and M. Oren Overproduction of p53 antigen makes established cells highly tumorigenic Nature 316 1985 158 160
102. D. Eliyahu, A. Raz, P. Gruss, D. Givol, and M. Oren Participation of p53 cellular tumour antigen in transformation of normal embryonic cells Nature 312 1984 646 649
103. S. Engelender, Z. Kaminsky, X. Guo, A.H. Sharp, R.K. Amaravi, and J.J. Kleiderlein et al. Synphilin-1 associates with a-synuclein and promotes the formation of cytosolic inclusions Nat Genet 22 1999 110 114
104. S.S. Fakharzadeh, S.P. Trusko, and D.L. George Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line EMBO J 10 1991 1565 1569
105. J. Fan, H. Ren, E. Fei, N. Jia, Z. Ying, and P. Jiang et al. Sumoylation is critical for DJ-1 to repress p53 transcriptional activity FEBS Lett 582 2008 1151 1156
106. J. Fan, H. Ren, N. Jia, E. Fei, T. Zhou, and P. Jiang et al. DJ-1 decreases Bax expression through repressing p53 transcriptional activity J Biol Chem 283 2008 4022 4030
107. Z. Feng, S. Jin, A. Zupnick, J. Hoh, E. de Stanchina, and S. Lowe et al. p53 tumor suppressor protein regulates the levels of huntingtin gene expression Oncogene 25 2006 1 7
108. G. Fenteany, and S.L. Schreiber Lactacystin, proteasome function, and cell fate J Biol Chem 273 1998 8545 8548
109. G. Fenteany, R. Standaert, W.S. Lane, S. Choi, E.J. Corey, and S.L. Schreiber Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin Science 268 1995 726 731
110. C.A. Finlay, P.W. Hinds, and A.J. Levine The p53 proto-oncogene can act as a suppressor of transformation Cell 57 1989 1083 1093
111. B. Flammang, R. Pardossi-Piquard, J. Sevalle, D. Debayle, A.S. Dabert-Gay, and A. Thevenet et al. Evidence that the amyloid-beta protein precursor intracellular domain, AICD, derives from beta-secretase-generated C-terminal fragment J Alzheimers Dis 30 2012 145 153
112. R. Fluhrer, G. Multhaup, A. Schlicksupp, M. Okochi, M. Takeda, and S. Lammich et al. Identification of a b-secretase activity, which truncates amyloid b-peptides after its presenilin-dependent generation J Biol Chem 278 2003 5531 5538
113. M.P. Fogarty, R.M. McCormack, J. Noonan, D. Murphy, A. Gowran, and V.A. Campbell A role for p53 in the beta-amyloid-mediated regulation of the lysosomal system Neurobiol Aging 31 2010 1774 1786
114. J. Folch, F. Junyent, E. Verdaguer, C. Auladell, J.G. Pizarro, and C. Beas-Zarate et al. Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death Neurotox Res 22 2012 195 207
115. F. Fornai, O.M. Schluter, P. Lenzi, M. Gesi, R. Ruffoli, and M. Ferrucci et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein Proc Natl Acad Sci U S A 102 2005 3413 3418
116. R. Francis, G. McGrath, J. Zhang, D.A. Ruddy, M. Sym, and J. Apfeld et al. aph-1 and pen2 are required for notch pathway signaling, g-secretase cleavage of bAPP and presenilin protein accumulation Dev Cell 3 2002 85 97
117. A. Friedler, L.O. Hansson, D.B. Veprintsev, S.M. Freund, T.M. Rippin, and Nikolova et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants Proc Natl Acad Sci U S A 99 2002 937 942
118. A. Friedler, D.B. Veprintesev, L.O. Hansson, and A.R. Fersht Kinetic instability of p53 core domain mutants. Implications for rescue by small molecules J Biol Chem 278 2003 24108 24112
119. T. Fujiwara, D.W. Cai, R.N. Georges, T. Mukhopadhyay, E.A. Grimm, and J.A. Roth Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model J Natl Cancer Inst 86 1994 1458 1462
120. G. Fulci, N. Ishii, and E.G. Van Meir p53 and brain tumors: from gene mutations to gene therapy Brain Pathol 8 1998 599 613
121. S. Funamoto, M. Morishima-Kawashima, Y. Tanimura, N. Hirotani, T.C. Saido, and M. Ihara Truncated carboxyl-terminal fragments of b-amyloid precursor protein are processed to amyloid b-proteins 40 and 42 Biochemistry 43 2004 13532 13540
122. W.D. Funk, D.T. Pak, R.H. Karas, W.E. Wright, and J.W. Shay A transcriptionally active DNA-binding site for human p53 protein complexes Mol Cell Biol 12 1992 2866 2871
123. F.B. Furnari, T. Fenton, R.M. Bachoo, A. Mukasa, J.M. Stommel, and A. Stegh et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes Dev 21 2007 2683 2710
124. S. Gandhi, and N.W. Wood Molecular pathogenesis of Parkinson's disease Hum Mol Genet 14 Spec No. 2 2005 2749 2755
125. T. Gasser Genetics of Parkinson's disease Clin Genet 54 1998 259 265
126. E. Giaime, C. Sunyach, C. Druon, S. Scarzello, G. Robert, and S. Grosso et al. Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6 Cell Death Differ 17 2010 158 169
127. E. Giaime, C. Sunyach, M. Herrant, S. Grosso, P. Auberger, and P.J. McLean et al. Caspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway J Biol Chem 281 2006 11515 11522
128. G.G. Glenner, and C.W. Wong Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein Biochem Biophys Res Commun 120 1984 885 890
129. C.J. Gloeckner, A. Schumacher, K. Boldt, and M. Ueffing The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro J Neurochem 109 2009 959 968
130. M. Goedert, M.G. Spillantini, K. Del Tredici, and H. Braak 100 years of Lewy pathology Nat Rev Neurol 9 2013 13 24
131. A.P. Goncalves, V. Maximo, J. Lima, K.K. Singh, P. Soares, and A. Videira Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone Biochim Biophys Acta 1813 2011 492 499
132. Z.V. Goodger, L. Rajendran, A. Trutzel, B.M. Kohli, R.M. Nitsch, and U. Konietzko Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway J Cell Sci 122 2009 3703 3714
133. D. Gosal, O.A. Ross, and M. Toft Parkinson's disease: the genetics of a heterogeneous disorder Eur J Neurol 13 2006 616 627
134. Y. Gu, H. Misonou, T. Sato, N. Dohmae, K. Takio, and Y. Ihara Distinct intramembrane cleavages of the b-amyloid precursor protein family resembling g-secretase-like cleavage of Notch J Biol Chem 276 2001 35235 35238
135. A.V. Gudkov, and E.A. Komarova Prospective therapeutic applications of p53 inhibitors Biochem Biophys Res Commun 331 2005 726 736
136. M.V. Guillot-Sestier, and F. Checler alpha-Secretase-derived cleavage of cellular prion yields biologically active catabolites with distinct functions Neurodegener Dis 10 2012 294 297
137. M.V. Guillot-Sestier, and F. Checler Cellular prion and its catabolites in the brain: production and function Curr Mol Med 12 2012 304 315
138. M.V. Guillot-Sestier, C. Sunyach, C. Druon, S. Scarzello, and F. Checler The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo J Biol Chem 284 2009 35973 35986
139. Q. Guo, L. Sebastian, B.L. Sopher, M.W. Miller, C.B. Ware, and G.M. Martin et al. Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid b-peptide toxicity: central roles of superoxide production and caspase activation J Neurochem 72 1999 1019 1029
140. K. Gwinn-Hardy, and A.A. Singleton Familial Lewy body diseases J Geriatr Psychiatry Neurol 15 2002 217 223
141. C. Hagel, G. Laking, R. Laas, S. Scheil, R. Jung, and K. Milde-Langosch et al. Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas Eur J Cancer 32A 1996 2242 2248
142. S.L. Harris, and A.J. Levine The p53 pathway: positive and negative feedback loops Oncogene 24 2005 2899 2908
143. M. Hartlage-Rubsamen, M. Morawski, A. Waniek, C. Jager, U. Zeitschel, and B. Koch et al. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Abeta deposits in hippocampus via distinct cellular mechanisms Acta Neuropathol 121 2011 705 719
144. A. Hartmann, and E.C. Hirsch Parkinson's disease. The apoptosis hypothesis revisited Adv Neurol 86 2001 143 153
145. M. Hashimoto, P. Bar-on, G. Ho, T. Takenouchi, E. Rockenstein, and L. Crews et al. b-synuclein regulates Akt activity in neuronal cells: a possible mechanism for neuroprotection in Parkinson's disease J Biol Chem 279 2004 23622 23629
146. Y. Haupt, R. Maya, A. Kazaz, and M. Oren Mdm2 promotes the rapid degradation of p53 Nature 387 1997 296 299
147. L. He, X. He, L.P. Lim, E. de Stanchina, Z. Xuan, and Y. Liang et al. A microRNA component of the p53 tumour suppressor network Nature 447 2007 1130 1134
148. L.E. Hebert, J. Weuve, P.A. Scherr, and D.A. Evans Alzheimer disease in the United States (2010-2050) estimated using the 2010 census Neurology 80 2013 1778 1783
149. H. Hermeking p53 enters the microRNA world Cancer Cell 12 2007 414 418
150. H. Hermeking The miR-34 family in cancer and apoptosis Cell Death Differ 17 2010 193 199
151. D.M. Holtzman, and C.J. Epstein The molecular genetics of Down syndrome Mol Genet Med 2 1992 105 120
152. D.M. Holtzman, E. Mandelkow, and D.J. Selkoe Alzheimer disease in 2020 Cold Spring Harb Perspect Med 2 2012
153. C. Hooper, E. Meimaridou, M. Tavassoli, G. Melino, S. Lovestone, and R. Killick p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells Neurosci Lett 418 2007 34 37
154. H. Houlden, and A.B. Singleton The genetics and neuropathology of Parkinson's disease Acta Neuropathol 124 2012 325 338
155. Q. Huang, and M.E. Figueiredo-Pereira Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications Apoptosis 15 2010 1292 1311
156. I. Hussain, D. Powell, D.R. Howlett, D.G. Tew, T.D. Meek, and C. Chapman et al. Identification of a novel aspartic protease (Asp2) as b-secretase Mol Cell Neurosci 14 1999 419 427
157. J.K. Jeong, M.H. Moon, J.W. Seol, J.S. Seo, Y.J. Lee, and S.Y. Park Prion peptide-mediated cellular prion protein overexpression and neuronal cell death can be blocked by aspirin treatment Int J Mol Med 27 2011 689 693
158. E. Junn, and M.M. Mouradian Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases J Neurochem 78 2001 374 383
159. T. Kamijo, J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 Proc Natl Acad Sci U S A 95 1998 8292 8297
160. Y.H. Kim, S. Nobusawa, M. Mittelbronn, W. Paulus, B. Brokinkel, and K. Keyvani et al. Molecular classification of low-grade diffuse gliomas Am J Pathol 177 2010 2708 2714
161. H.S. Kim, C.H. Park, S.H. Cha, J.H. Lee, S. Lee, and Y. Kim et al. Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity FASEB J 14 2000 1508 1517
162. H.S. Kim, C.H. Park, and Y.H. Suh C-terminal fragment of amyloid precursor protein inhibits calcium uptake into rat brain microsomes by Mg2+-Ca2+ ATPase Neuroreport 9 1998 3875 3879
163. S.H. Kim, and Y.H. Suh Neurotoxicity of a carboxyl-terminal fragment of the Alzheimer's amyloid precursor protein J Neurochem 67 1996 1172 1182
164. W.T. Kimberly, M.J. LaVoie, B.L. Ostaszewski, W. Ye, M.S. Wolfe, and D.J. Selkoe g-secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1 and pen-2 Proc Natl Acad Sci U S A 100 2003 6382 6387
165. R.M. Kirla, H.K. Haapasalo, H. Kalimo, and E.K. Salminen Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas Cancer 97 2003 644 648
166. T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, and S. Minoshima et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 392 1998 605 608
167. Y. Kitamura, S. Shimohama, W. Kamoshima, Y. Matsuoka, Y. Nomura, and T. Taniguchi Changes of p53 in the brains of patients with Alzheimer's disease Biochem Biophys Res Commun 232 1997 418 421
168. C. Klein, and M.G. Schlossmacher Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder Neurology 69 2007 2093 2104
169. W.P. Kloosterman, and R.H. Plasterk The diverse functions of microRNAs in animal development and disease Dev Cell 11 2006 441 450
170. K. Kobayashi, M. Hayashi, H. Nakano, M. Shimazaki, K. Sugimori, and Y. Koshino Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease J Alzheimers Dis 6 2004 623 632 (discussion 673-681)
171. P.G. Komarov, E.A. Komarova, R.V. Kondratov, K. Christov-Tselkov, J.S. Coon, and M.V. Chernov et al. A chemical inhibitor of p53 that protects mice from the side effect of cancer therapy Science 285 1999 1733 1737
172. P.G. Komarov, E.A. Komarova, R.V. Kondratov, K. Christov-Tselkov, J.S. Coon, and M.V. Chernov et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy Science 285 1999 1733 1737
173. U. Konietzko AICD nuclear signaling and its possible contribution to Alzheimer's disease Curr Alzheimer Res 9 2012 200 216
174. G.G. Kovacs, and H. Budka Distribution of apoptosis-related proteins in sporadic Creutzfeldt-Jakob disease Brain Res 1323 2010 192 199
175. M.H. Kubbutat, S.N. Jones, and K.H. Vousden Regulation of p53 stability by Mdm2 Nature 387 1997 299 303
176. K.R. Kumar, K. Lohmann, and C. Klein Genetics of Parkinson disease and other movement disorders Curr Opin Neurol 25 2012 466 474
177. J.W. Kusiak, J.A. Izzo, and B. Zhao Neurodegeneration in Alzheimer disease. Is apoptosis involved? Mol Chem Neuropathol 28 1996 153 162
178. D.P. Lane, and L.V. Crawford T antigen is bound to a host protein in SV40-transformed cells Nature 278 1979 261 263
179. D. Lane, and A. Levine p53 research: the past thirty years and the next thirty years Cold Spring Harb Perspect Biol 2 2010 a000893
180. C. Lanni, M. Racchi, S. Stanga, G. Mazzini, A. Ranzenigo, and R. Polotti et al. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease J Alzheimers Dis 20 2010 97 104
181. H. Lassmann, C. Bancher, H. Breitschopf, J. Wegiel, M. Bobinski, and K. Jellinger et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ Acta Neuropathol 89 1995 35 41
182. J.T. Lee, and W. Gu The multiple levels of regulation by p53 ubiquitination Cell Death Differ 17 2010 86 92
183. S.J. Lee, D.C. Kim, B.H. Choi, H. Ha, and K.T. Kim Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death J Biol Chem 281 2006 2215 2224
184. V.M.-Y. Lee, and J.Q. Trojanowski Neurodegenerative tauopathies: human disease and transgenic mouse models Neuron 24 1999 507 510
185. S. Lefranc-Jullien, C. Sunyach, and F. Checler The ε-secretase- derived N-terminal product of the β-amyloid precursor protein behaves as a membrane-bound protein and undergoes α-, β-, and γ-secretases cleavages J Neurochem 97 2006 807 817
186. N. Lev, E. Melamed, and D. Offen Apoptosis and Parkinson's disease Prog Neuropsychopharmacol Biol Psychiatry 27 2003 245 250
187. G. Levidou, E. El-Habr, A.A. Saetta, C. Bamias, K. Katsouyanni, and E. Patsouris et al. P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature J Neurooncol 100 2010 363 371
188. A.J. Levine, and M. Oren The first 30 years of p53: growing ever more complex Nat Rev Cancer 9 2009 749 758
189. X.L. Li, G.R. Wang, Y.Y. Jing, M.M. Pan, C.F. Dong, and R.M. Zhou et al. Cytosolic PrP induces apoptosis of cell by disrupting microtubule assembly J Mol Neurosci 43 2011 316 325
190. J. Liang, D. Parchaliuk, S. Medina, G. Sorensen, L. Landry, and S. Huang et al. Activation of p53-regulated pro-apoptotic signaling pathways in PrP-mediated myopathy BMC Genomics 10 2009 201
191. X. Lin, G. Koelsch, S. Wu, D. Downs, A. Dashti, and J. Tang Human aspartyl protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein Proc Natl Acad Sci U S A 97 2000 1456 1460
192. R. Linden, V.R. Martins, M.A. Prado, M. Cammarota, I. Izquierdo, and R.R. Brentani Physiology of the prion protein Physiol Rev 88 2008 673 728
193. D.I. Linzer, and A.J. Levine Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells Cell 17 1979 43 52
194. F. Lombino, F. Biundo, R. Tamayev, O. Arancio, and L. D'Adamio An intracellular threonine of amyloid-beta precursor protein mediates synaptic plasticity deficits and memory loss PLoS One 8 2013 e57120
195. M.H. Lopes, G.N. Hajj, A.G. Muras, G.L. Mancini, R.M. Castro, and K.C. Ribeiro et al. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways J Neurosci 25 2005 11330 11339
196. I.T. Lott Down's syndrome, aging, and Alzheimer's disease: a clinical review Ann N Y Acad Sci 396 1982 15 27
197. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, and A. Jouvet et al. The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 2007 97 109
198. Q.R. Lu, J.K. Park, E. Noll, J.A. Chan, J. Alberta, and D. Yuk et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors Proc Natl Acad Sci U S A 98 2001 10851 10856
199. D.C. Lu, S. Rabizadeh, S. Chandra, R.F. Shayya, L.M. Ellerby, and X. Ye et al. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor Nat Med 6 2000 397 404
200. J. Lyahyai, R. Bolea, C. Serrano, E. Vidal, M. Pumarola, and J.J. Badiola et al. Differential expression and protein distribution of Bax in natural scrapie Brain Res 1180 2007 111 120
201. S.L. Ma, L. Pastorino, X.Z. Zhou, and K.P. Lu Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3beta (GSK3beta) activity: novel mechanism for Pin1 to protect against Alzheimer disease J Biol Chem 287 2012 6969 6973
202. D. Maintz, K. Fiedler, J. Koopmann, B. Rollbrocker, S. Nechev, and D. Lenartz et al. Molecular genetic evidence for subtypes of oligoastrocytomas J Neuropathol Exp Neurol 56 1997 1098 1104
203. E. Mandelkow The tangled tale of tau Nature 402 1999 588 589
204. D.M. Mann Alzheimer's disease and Down's syndrome Histopathology 13 1988 125 137
205. E. Maries, B. Dass, T.J. Collier, J.H. Kordower, and K. Steece-Collier The role of alpha-synuclein in Parkinson's disease: insights from animal models Nat Rev Neurosci 4 2003 727 738
206. L.J. Martin, Y. Pan, A.C. Price, W. Sterling, N.G. Copeland, and N.A. Jenkins et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death J Neurosci 26 2006 41 50
207. D. Martin, M. Salinas, R. Lopez-Valdaliso, E. Serrano, M. Recuero, and A. Cuadrado Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells J Neurochem 78 2001 1000 1008
208. W. Maruyama, and M. Naoi Cell death in Parkinson's disease J Neurol 249 Suppl. 2 2002 II6 II10
209. E. Masliah, M. Mallory, M. Alford, S. Tanaka, and L.A. Hansen Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease J Neuropathol Exp Neurol 57 1998 1041 1052
210. M.M. Maslon, and T.R. Hupp Drug discovery and mutant p53 Trends Cell Biol 20 2010 542 555
211. C.L. Masters, G. Simons, N.A. Weinman, G. Multhaup, B.L. Mc Donald, and K. Beyreuther Amyloid plaque core protein in Alzheimer's Disease and Down Syndrome Proc Natl Acad Sci U S A 82 1985 4245 4249
212. T. Matsui, K. Ramasamy, M. Ingelsson, H. Fukumoto, C. Conrad, and M.P. Frosch et al. Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels J Neuropathol Exp Neurol 65 2006 508 515
213. V. Mattei, P. Matarrese, T. Garofalo, A. Tinari, L. Gambardella, and L. Ciarlo et al. Recruitment of cellular prion protein to mitochondrial raft-like microdomains contributes to apoptosis execution Mol Biol Cell 22 2011 4842 4853
214. S.M. Mendrysa, S. Ghassemifar, and R. Malek p53 in the CNS: perspectives on development, stem cells, and cancer Genes Cancer 2 2011 431 442
215. J. Meunier, J. Ieni, and T. Maurice The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor Br J Pharmacol 149 2006 998 1012
216. J. Milosevic, S.C. Schwarz, V. Ogunlade, A.K. Meyer, A. Storch, and J. Schwarz Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation Mol Neurodegener 4 2009 25
217. M.A. Mittler, B.C. Walters, and E.G. Stopa Observer reliability in histological grading of astrocytoma stereotactic biopsies J Neurosurg 85 1996 1091 1094
218. Y. Mizuno, N. Hattori, H. Mori, T. Suzuki, and K. Tanaka Parkin and Parkinson's disease Curr Opin Neurol 14 2001 477 482
219. H. Mochizuki, K. Goto, H. Mori, and Y. Mizuno Histochemical detection of apoptosis in Parkinson's disease J Neurol Sci 137 1996 120 123
220. M. Mogi, T. Kondo, Y. Mizuno, and T. Nagatsu p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain Neurosci Lett 414 2007 94 97
221. U.M. Moll, M. LaQuaglia, J. Benard, and G. Riou Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors Proc Natl Acad Sci U S A 92 1995 4407 4411
222. U.M. Moll, G. Riou, and A.J. Levine Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion Proc Natl Acad Sci U S A 89 1992 7262 7266
223. J. Momand, G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 69 1992 1237 1245
224. P. Mookherjee, and G.V. Johnson Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells Brain Res 921 2001 31 43
225. C. Moon, Y. Oh, and J.A. Roth Current status of gene therapy for lung cancer and head and neck cancer Clin Cancer Res 9 2003 5055 5067
226. H.R. Morris Genetics of Parkinson's disease Ann Med 37 2005 86 96
227. P. Muller, P. Ceskova, and B. Vojtesek Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy J Biol Chem 280 2005 6682 6691
228. M. Musicco, F. Adorni, S. Di Santo, F. Prinelli, C. Pettenati, and C. Caltagirone et al. Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study Neurology 81 2013 322 328
229. T. Nagatsu Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy J Neural Transm 109 2002 731 745
230. V.D. Nair Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease Apoptosis 11 2006 955 966
231. V.D. Nair, K.S. McNaught, J. Gonzalez-Maeso, S.C. Sealfon, and C.W. Olanow p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition J Biol Chem 281 2006 39550 39560
232. Y. Nakamura Isolation of p53-target genes and their functional analysis Cancer Sci 95 2004 7 11
233. A.Y. Nikolaev, M. Li, N. Puskas, J. Qin, and W. Gu Parc: a cytoplasmic anchor for p53 Cell 112 2003 29 40
234. A. Ning, J. Cui, E. To, K.H. Ashe, and J. Matsubara Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease Invest Ophthalmol Vis Sci 49 2008 5136 5143
235. M. Nozaki, M. Tada, H. Kobayashi, C.L. Zhang, Y. Sawamura, and H. Abe et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression Neuro Oncol 1 1999 124 137
236. H. Ohgaki, P. Dessen, B. Jourde, S. Horstmann, T. Nishikawa, and P.L. Di Patre et al. Genetic pathways to glioblastoma: a population-based study Cancer Res 64 2004 6892 6899
237. H. Ohgaki, and P. Kleihues Epidemiology and etiology of gliomas Acta Neuropathol 109 2005 93 108
238. H. Ohgaki, and P. Kleihues Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas J Neuropathol Exp Neurol 64 2005 479 489
239. H. Ohgaki, and P. Kleihues Genetic pathways to primary and secondary glioblastoma Am J Pathol 170 2007 1445 1453
240. H. Ohgaki, and P. Kleihues Genetic profile of astrocytic and oligodendroglial gliomas Brain Tumor Pathol 28 2011 177 183
241. Y. Ohyagi, H. Asahara, D.H. Chui, Y. Tsuruta, N. Sakae, and K. Miyoshi et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease FASEB J 19 2005 255 257
242. Y. Ohyagi, T. Yamada, K. Nishioka, N.J. Clarke, A.J. Tomlinson, and S. Naylor et al. Selective increase in cellular A beta 42 is related to apoptosis but not necrosis Neuroreport 11 2000 167 171
243. J.D. Oliner, J.A. Pietenpol, S. Thiagalingam, J. Gyuris, K.W. Kinzler, and B. Vogelstein Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 Nature 362 1993 857 860
244. M. Olivier, M. Hollstein, and P. Hainaut TP53 mutations in human cancers: origins, consequences, and clinical use Cold Spring Harb Perspect Biol 2 2010 a001008
245. J.A. Olzmann, K. Brown, K.D. Wilkinson, H.D. Rees, Q. Huai, and H. Ke et al. Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function J Biol Chem 279 2003 8506 8515
246. D. Ottolini, T. Cali, A. Negro, and M. Brini The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering Hum Mol Genet 22 2013 2152 2168
247. B. Oulès, D. Del Prete, B. Greco, X. Zhang, I. Lauritzen, and J. Sevalle et al. Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease J Neurosci 32 2012 11820 11834
248. T. Ozaki, Y. Li, H. Kikuchi, T. Tomita, T. Iwatsubo, and A. Nakagawara The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis Biochem Biophys Res Commun 351 2006 57 63
249. C. Paisan-Ruiz, S. Jain, E.W. Evans, W.P. Gilks, J. Simon, and M. van den Brug et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 44 2004 595 600
250. c triggers caspase 3 activation: potentiation by proteasome inhibitors and blockade by anti-PrP antibodies J Neurochem 83 2002 1208 1214
251. E. Paitel, R. Fahraeus, and F. Checler Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation J Biol Chem 278 2003 10061 10066
252. E. Paitel, C. Sunyach, C. Alves da Costa, J.C. Bourdon, B. Vincent, and F. Checler Primary cultured neurons devoid of cellular prion display lower responsiveness to staurosporine through the control of p53 at both transcriptional and post-transcriptional levels J Biol Chem 279 2004 612 618
253. R. Pardossi-Piquard, and F. Checler The physiology of the beta-amyloid precursor protein intracellular domain AICD J Neurochem 120 Suppl. 1 2012 109 124
254. R. Pardossi-Piquard, J. Dunys, E. Giaime, M.V. Guillot-Sestier, P. St George-Hyslop, and F. Checler et al. p53-dependent control of cell death by nicastrin: lack of requirement for presenilin-dependent gamma-secretase complex J Neurochem 109 2009 225 237
255. D.W. Parsons, S. Jones, X. Zhang, J.C. Lin, R.J. Leary, and P. Angenendt et al. An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
256. B. Passer, L. Pellegrini, C. Russo, R.M. Siegel, M.J. Lenardio, and G. Schettini et al. Generation of an apoptotic intracellular peptide by g-secretase cleavage of Alzheimer's amyloid b protein precursor J Alzheimers Dis 2 2000 289 301
257. L. Pastorino, S.L. Ma, M. Balastik, P. Huang, D. Pandya, and L. Nicholson et al. Alzheimer's disease-related loss of Pin1 function influences the intracellular localization and the processing of AbetaPP J Alzheimers Dis 30 2012 277 297
258. J.L. Perfettini, M. Castedo, R. Nardacci, F. Ciccosanti, P. Boya, and T. Roumier et al. Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope J Exp Med 201 2005 279 289
259. A. Petit, F. Bihel, C. Alves da Costa, O. Pourquie, F. Checler, and J.L. Kraus New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage Nat Cell Biol 3 2001 507 511
260. A. Petitjean, E. Mathe, S. Kato, C. Ishioka, S.V. Tavtigian, and P. Hainaut et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database Hum Mutat 28 2007 622 629
261. M. Peuchmaur, M.A. Lacour, J. Sevalle, V. Lisowski, Y. Touati-Jallabe, and F. Rodier et al. Further characterization of a putative serine protease contributing to the gamma-secretase cleavage of beta-amyloid precursor protein Bioorg Med Chem 21 2013 1018 1029
262. M. Pietri, C. Dakowski, S. Hannoui, A. Alleaume-Butaux, J. Hernandez-Rapp, and A. Ragagnin et al. PDK1 decreases TACE-mediated alpha-secretase activity and promotes disease progression in prion and Alzheimer's diseases Nat Med 19 2013 1124 1131
263. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, and A. Dutra et al. Mutation in the a-synuclein gene identified in families with Parkinson Disease Science 276 1997 2045 2047
264. J. Pomerantz, N. Schreiber-Agus, N.J. Liegeois, A. Silverman, L. Alland, and L. Chin et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 92 1998 713 723
265. A. Prestia, A. Caroli, W.M. van der Flier, R. Ossenkoppele, B. Van Berckel, and F. Barkhof et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease Neurology 80 2013 1048 1056
266. S.B. Prusiner Prions Proc Natl Acad Sci U S A 95 1998 13363 13383
267. R. Rahman-Roblick, U. Hellman, S. Becker, F.G. Bader, G. Auer, and K.G. Wiman et al. Proteomic identification of p53-dependent protein phosphorylation Oncogene 27 2008 4854 4859
268. N. Raver-Shapira, E. Marciano, E. Meiri, Y. Spector, N. Rosenfeld, and N. Moskovits et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis Mol Cell 26 2007 731 743
269. G. Robert, A. Puissant, M. Dufies, S. Marchetti, A. Jacquel, and T. Cluzeau et al. The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production Cell Death Differ 19 2012 1769 1778
270. A.I. Robles, and C.C. Harris Clinical outcomes and correlates of TP53 mutations and cancer Cold Spring Harb Perspect Biol 2 2010 a001016
271. C.M. Roe, M.I. Behrens, C. Xiong, J.P. Miller, and J.C. Morris Alzheimer disease and cancer Neurology 64 2005 895 898
272. E.I. Rogaev, R. Sherrington, E.A. Rogaeva, G. Levesque, M. Ikeda, and Y. Liang et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene Nature 376 1995 775 778
273. J.P. Roperch, V. Alvaro, S. Prieur, M. Tuynder, M. Nemani, and F. Lethrosne et al. Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression Nat Med 4 1998 835 838
274. S. Rosner, N. Giladi, and A. Orr-Urtreger Advances in the genetics of Parkinson's disease Acta Pharmacol Sin 29 2008 21 34
275. A. Sailer, H. Bueler, M. Fischer, A. Aguzzi, and C. Weissmann No propagation of prions in mice devoid of PrP Cell 77 1994 967 968
276. F.D. Sajan, F. Martiniuk, D.L. Marcus, W.H. Frey 2nd, R. Hite, and E.Z. Bordayo et al. Apoptotic gene expression in Alzheimer's disease hippocampal tissue Am J Alzheimers Dis Other Demen 22 2007 319 328
277. M. Sasaki, L. Nie, and C.G. Maki MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation J Biol Chem 282 2007 14626 14634
278. M. Sastre, H. Steiner, K. Fuchs, A. Capell, G. Multhaup, and M.M. Condron et al. Presenilin dependent g-secretase processing of b-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch EMBO Rep 2 2001 835 841
279. R. Scardigli, G. Bossi, G. Blandino, M. Crescenzi, S. Soddu, and A. Sacchi Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging Gene Ther 4 1997 1371 1378
280. A.H. Schapira, and P. Jenner Etiology and pathogenesis of Parkinson's disease Mov Disord 26 2011 1049 1055
281. H.M. Schatzl, L. Laszlo, D.M. Holtzman, J. Tatzelt, S.J. DeArmond, and R.I. Weiner et al. A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis J Virol 71 1997 8821 8831
282. M. Scheffner Ubiquitin, E6-AP, and their role in p53 inactivation Pharmacol Ther 78 1998 129 139
283. S. Schilling, U. Zeitschel, T. Hoffmann, U. Heiser, M. Francke, and A. Kehlen et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology Nat Med 14 2008 1106 1111
284. R. Seidl, S. Fang-Kircher, B. Bidmon, N. Cairns, and G. Lubec Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down syndrome Neurosci Lett 260 1999 9 12
285. D.J. Selkoe The molecular pathology of Alzheimer's disease Neuron 6 1991 487 498
286. O. Sembritzki, C. Hagel, K. Lamszus, W. Deppert, and W. Bohn Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein Neuro Oncol 4 2002 171 178
287. J. Sevalle, A. Amoyel, P. Robert, M.C. Fournie-Zaluski, B. Roques, and F. Checler Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide J Neurochem 109 2009 248 256
288. M.E. Seward, E. Sanson, A. Norambuena, A. Reimann, J.N. Cochran, and R. Li et al. Amyloid-beta signas through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease J Cell Sci 126 2013 1278 1286
289. R. Sherrington, S. Froelich, S. Sorbi, D. Campion, H. Chi, and E.A. Rogaeva et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant Hum Mol Genet 5 1996 985 988
290. X.P. Shi, K. Tugusheva, J.E. Bruce, A. Lucka, G.X. Wu, and E. Chen-Dodson et al. Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity J Biol Chem 278 2003 21286 21294
291. H. Shimura, N. Hattori, S. Kubo, Y. Mizuno, S. Asakawa, and S. Minoshima et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase Nat Genet 25 2000 302 305
292. Y. Shinbo, T. Taira, T. Niki, S.M. Iguchi-Ariga, and H. Ariga DJ-1 restores p53 transcription activity inhibited by Topors/p53BP3 Int J Oncol 26 2005 641 648
293. D. Shmerling, I. Hegyi, M. Fischer, T. Blattler, S. Brandner, and J. Gotz et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions Cell 93 1998 203 214
294. F. Simunovic, M. Yi, Y. Wang, L. Macey, L.T. Brown, and A.M. Krichevsky et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology Brain 132 2009 1795 1809
295. N. Singh, Y. Gu, S. Bose, S. Kalepu, R.S. Mishra, and S. Verghese Prion peptide 106-126 as a model for prion replication and neurotoxicity Front Biosci 7 2002 a60 a71
296. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, and J. Kachergus et al. Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003
297. S. Sinha, J.P. Anderson, R. Barbour, G.S. Basi, R. Caccavello, and D. Davis et al. Purification and cloning of amyloid precursor protein b-secretase from human brain Nature 402 1999 537 540
298. W.W. Smith, Z. Liu, Y. Liang, N. Masuda, D.A. Swing, and N.A. Jenkins et al. Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model Hum Mol Genet 19 2010 2087 2098
299. M. Sorice, V. Mattei, V. Tasciotti, V. Manganelli, T. Garofalo, and R. Misasi Trafficking of PrPc to mitochondrial raft-like microdomains during cell apoptosis Prion 6 2012 354 358
300. M.G. Spillantini, and M. Goedert Tau protein pathology in neurodegenerative diseases TIN 21 1998 428 433
301. V. Stambolic, D. MacPherson, D. Sas, Y. Lin, B. Snow, and Y. Jang et al. Regulation of PTEN transcription by p53 Mol Cell 8 2001 317 325
302. M. Stander, A. Peraud, B. Leroch, and F.W. Kreth Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis Cancer 101 2004 1028 1035
303. J.H. Su, A.J. Anderson, B.J. Cummings, and C.W. Cotman Immunohistochemical evidence for apoptosis in Alzheimer's disease Neuroreport 5 1994 2529 2533
304. J.H. Su, T. Satou, A.J. Anderson, and C.W. Cotman Up-regulation of Bcl-2 is associated with neuronal DNA damage in Alzheimer's disease Neuroreport 7 1996 437 440
305. Y.H. Suh, and F. Checler Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease Pharmacol Rev 54 2002 469 525
306. C. Sunico, T. Nakamura, E. Rockenstein, M. Mante, A. Adame, and S. Chan et al. S-nitrosylaton of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease Mol Neurodegener 8 2013 10.1186/1750-1326-8-29 (in press)
307. C. Sunyach, and F. Checler Combined pharmacological, mutational and cell biology approaches indicate that p53-dependent caspase 3 activation triggered by cellular prion is dependent on its endocytosis J Neurochem 92 2005 1399 1407
308. C. Sunyach, M.A. Cisse, C.A. da Costa, B. Vincent, and F. Checler The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine-induced caspase-3 activation J Biol Chem 282 2007 1956 1963
309. A. Surguchov Molecular and cellular biology of synucleins Int Rev Cell Mol Biol 270 2008 225 317
310. K. Takahashi, C. Uchida, R.W. Shin, K. Shimazaki, and T. Uchida Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer's disease Cell Mol Life Sci 65 2008 359 375
311. N. Takasugi, T. Tomita, I. Hayashi, M. Tsuruoka, M. Niimura, and Y. Takahashi et al. The role of presenilin cofactors in the g-secretase complex Nature 422 2003 438 441
312. N. Tatton, and S. Kish In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining Neuroscience 77 1997 1037 1048
313. D.R. Taylor, E.T. Parkin, S.L. Cocklin, J.R. Ault, A.E. Ashcroft, and A.J. Turner et al. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein J Biol Chem 284 2009 22590 22600
314. T.L. Tekirian, T.C. Saido, W.R. Markesbery, M.J. Russell, D.R. Wekstein, and E. Patel et al. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposit J Neuropathol Exp Neurol 57 1998 76 94
315. S. Thellung, A. Corsaro, V. Villa, A. Simi, S. Vella, and A. Pagano et al. Human PrP90-231-induced cell death is associated with intracellular accumulation of insoluble and protease-resistant macroaggregates and lysosomal dysfunction Cell Death Dis 2 2011 e138
316. F. Toledo, and G.M. Wahl MDM2 and MDM4: p53 regulators as targets in anticancer therapy Int J Biochem Cell Biol 39 2007 1476 1482
317. P.A. Trimmer, T.S. Smith, A.B. Jung, and J.P.J. Bennett Dopaminergic neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity Neurodegeneration 5 1996 233 239
318. J. Trinh, and M. Farrer Advances in the genetics of Parkinson disease Nat Rev Neurol 9 2013 445 454
319. J.Q. Trojanowski, and V.M. Lee Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia Arch Neurol 55 1998 151 152
320. D. Uberti, C. Lanni, T. Carsana, S. Francisconi, C. Missale, and M. Racchi et al. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients Neurobiol Aging 27 2006 1193 1201
321. D. Uberti, C. Lanni, M. Racchi, S. Govoni, and M. Memo Conformationally altered p53: a putative peripheral marker for Alzheimer's disease Neurodegener Dis 5 2008 209 211
322. D. Uberti, T. Carsana, E. Bernardi, L. Rodella, P. Grigolato, and C. Lanni et al. Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients J Cell Sci 115 2002 3131 3138
323. M.A. Valencia-Sanchez, J. Liu, G.J. Hannon, and R. Parker Control of translation and mRNA degradation by miRNAs and siRNAs Genes Dev 20 2006 515 524
324. E.M. Valente, P.M. Abou-Sleiman, V. Caputo, M.M. Muqit, K. Harvey, and S. Gispert et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science 304 2004 1158 1160
325. R. Vassar, B.D. Bennett, S. Babu-Khan, S. Khan, E.A. Mendiaz, and P. Denis et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE Science 286 1999 735 741
326. C. Velez-Pardo, G.G. Ospina, and M. Jimenez del Rio Abeta[25-35] peptide and iron promote apoptosis in lymphocytes by an oxidative stress mechanism: involvement of H2O2, caspase-3, NF-kappaB, p53 and c-Jun Neurotoxicology 23 2002 351 365
327. F. Villarejo, J.M. de Diego, and A.G. de la Riva Prognosis of cerebellar astrocytomas in children Childs Nerv Syst 24 2008 203 210
328. B. Vincent, E. Paitel, Y. Frobert, S. Lehmann, J. Grassi, and F. Checler Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons J Biol Chem 275 2000 35612 35616
329. B. Vincent, E. Paitel, P. Saftig, Y. Frobert, D. Hartmann, and B. De Strooper et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein J Biol Chem 276 2001 37743 37746
330. B. Vincent, C. Sunyach, H.D. Orzechowski, P. St George-Hyslop, and F. Checler p53-Dependent transcriptional control of cellular prion by presenilins J Neurosci 29 2009 6752 6760
331. J. Viotti, E. Duplan, C. Caillava, J. Condat, T. Goiran, and C. Giordano et al. Glioma Tumor Grades Correlates With Parkin Depletion in Mutant p53-linked Tumors and Results From Loss of Function of p53 Transcriptional Activity 2013 10.1038/onc.2013.124 (in press)
332. B. Vogelstein, and K.W. Kinzler p53 function and dysfunction Cell 70 1992 523 526
333. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
334. K. Von Eckardstein, H. Gries, E. Bolik, J. Cervos-Navarro, I.N. Tschairkin, and S. Patt p53 mutation and protein alteration in 50 gliomas Retrospective study by DNA-sequencing techniques and immunohistochemistry. Histol Histopathol 12 3 1997 611 616
335. K.H. Vousden, and X. Lu Live or let die: the cell's response to p53 Nat Rev Cancer 2 2002 594 604
336. K. Wakabayashi, S. Engelender, M. Yoshimoto, S. Tsuji, C.A. Ross, and H. Takahashi Synphilin-1 is present in Lewy bodies in Parkinson's disease Ann Neurol 47 2000 521 523
337. S. Wang, B.P. Simon, D.A. Bennett, J.A. Schneider, J.S. Malter, and D.S. Wang The significance of Pin1 in the development of Alzheimer's disease J Alzheimers Dis 11 2007 13 23
338. X. Wang, F. Wang, M.S. Sy, and J. Ma Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol J Biol Chem 280 2005 317 325
339. K. Watanabe, K. Sato, W. Biernat, O. Tachibana, K. von Ammon, and N. Ogata et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies Clin Cancer Res 3 1997 523 530
340. T. Watanabe, H. Yokoo, M. Yokoo, Y. Yonekawa, P. Kleihues, and H. Ohgaki Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas J Neuropathol Exp Neurol 60 2001 1181 1189
341. B. Wawrzynow, A. Zylicz, M. Wallace, T. Hupp, and M. Zylicz MDM2 chaperones the p53 tumor suppressor J Biol Chem 282 2007 32603 32612
342. A. Weidemann, S. Eggert, F.B.M. Reinhard, M. Vogel, K. Paliga, and G. Baier et al. A novel e-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with the Notch processing Biochemistry 41 2002 2825 2835
343. C. Weissmann, M. Enari, P.-C. Klöhn, D. Rossi, and E. Flechsig Molecular biology of prions Acta Neurobiol Exp 62 2002 153 166
344. M. Weller, J. Felsberg, C. Hartmann, H. Berger, J.P. Steinbach, and J. Schramm et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network J Clin Oncol 27 2009 5743 5750
345. O. Wirths, H. Breyhan, H. Cynis, S. Schilling, H.U. Demuth, and T.A. Bayer Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model Acta Neuropathol 118 2009 487 496
346. M.G. Woo, K. Xue, J. Liu, H. McBride, and B.K. Tsang Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking J Biol Chem 287 2012 3963 3975
347. M. Wrensch, Y. Minn, T. Chew, M. Bondy, and M.S. Berger Epidemiology of primary brain tumors: current concepts and review of the literature Neuro Oncol 4 2002 278 299
348. F. Wu, Z. Wang, J.H. Gu, J.B. Ge, Z.Q. Liang, and Z.H. Qin p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease Neurochem Int 63 2013 133 140
349. Z. Xu, D. Cawthon, K.A. McCastlain, H.M. Duhart, G.D. Newport, and H. Fang et al. Selective alterations of transcription factors in MPP+-induced neurotoxicity in PC12 cells Neurotoxicology 26 2005 729 737
350. Z. Xu, D. Cawthon, K.A. McCastlain, W. Slikker Jr., and S.F. Ali Selective alterations of gene expression in mice induced by MPTP Synapse 55 2005 45 51
351. R. Yan, M.J. Bienkowski, M.E. Shuck, H. Miao, M.C. Tory, and A.M. Pauley et al. Membrane-anchored aspartyl protease with Alzheimer's disease b-secretase activity Nature 402 1999 533 537
352. F. Yang, X. Sun, W. Beech, B. Teter, S. Wu, and J. Sigel et al. Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease Am J Pathol 152 1998 379 389
353. B.A. Yankner New clues to Alzheimer's disease: unraveling the roles of amyloid and tau Nat Med 2 1996 850 852
354. Y.H. Yap, and Y.H. Say Resistance against apoptosis by the cellular prion protein is dependent on its glycosylation status in oral HSC-2 and colon LS 174T cancer cells Cancer Lett 306 2011 111 119
355. Y.H. Yap, and Y.H. Say Resistance against tumour necrosis factor alpha apoptosis by the cellular prion protein is cell-specific for oral, colon and kidney cancer cell lines Cell Biol Int 36 2012 273 277
356. G. Yu, M. Nishimura, S. Arawaka, D. Levitan, L. Zhang, and A. Tandon et al. Nicastrin modulates presenilin-mediated notch/glp1 signal transduction and bAPP processing Nature 407 2000 48 54
357. S.M. Zanata, M.H. Lopes, A.F. Mercadante, G.N. Hajj, L.B. Chiarini, and
358. A.G. Zeimet, and C. Marth Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 4 2003 415 422
359. C. Zhang, M. Lin, R. Wu, X. Wang, B. Yang, and A.J. Levine et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect Proc Natl Acad Sci U S A 108 2011 16259 16264
360. H. Zheng, H. Ying, H. Yan, A.C. Kimmelman, D.J. Hiller, and A.J. Chen et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation Nature 455 2008 1129 1133
361. M. Zhou, G. Ottenberg, G.F. Sferrazza, and C.I. Lasmezas Highly neurotoxic monomeric alpha-helical prion protein Proc Natl Acad Sci U S A 109 2012 3113 3118
362. H.Y. Zhou, Y.Y. Tan, Z.Q. Wang, G. Wang, G.Q. Lu, and S.D. Chen Proteasome inhibitor lactacystin induces cholinergic degeneration Can J Neurol Sci 37 2010 229 234
363. H.B. Zhu, K. Yang, Y.Q. Xie, Y.W. Lin, Q.Q. Mao, and L.P. Xie Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells World J Surg Oncol 11 2013 22
364. X. Zhu, Q.S. Yu, R.G. Cutler, C.W. Culmsee, H.W. Holloway, and D.K. Lahiri et al. Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives J Med Chem 45 2002 5090 5097
365. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, and S. Lincoln et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology Neuron 44 2004 601 607